microdosing glp-1 for autoimmune Hashimoto's: Evidence, Risks and NHS Guidance – Bolt Pharmacy Why GLP-1 Microdosing? A Closer

Warning Signs: What to Look For Pancreatitis is an inflammation of the pancreas, a gland located behind your stomach

Effect of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure: A Network Meta-Analysis

The concept of signaling bias, the preferential activation of one intracellular signaling pathway over another, has been intensively studied in the GLP-1 receptor field

Many trials were designed to explore cardiovascular safety or benefit using SGLT2i molecules, including empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin, which greatly differ in their characteristics, including the number of participants, study duration, the inclusion of patients with HF or renal disease, HF characterized by reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF), and associated comorbidities or risk factors, clearly implying differences in the risk and rate of cardiovascular or renal events recorded during the investigations [2]

This included heart attack and stroke, by 20% in adults with obesity or overweight who already had cardiovascular disease, even without diabetes (Reference)

This is one area where MEDVi provider involvement adds genuine value, since the choice between these two medications depends on factors like individual side effect profiles , metabolic status, and treatment goals